Background: A major problem in craniofacial surgery is non-healing bone defects. Autologous reconstruction remains the standard of care for these cases. Bone morphogenetic protein-2 (BMP-2) therapy has proven its clinical utility, although non-targeted adverse events occur due to the high milligram-level doses used. Ongoing efforts explore the use of different growth factors, cytokines, or chemokines, as well as co-therapy to augment healing. Methods: Here we utilize inkjet-based biopatterning to load acellular DermaMatrix delivery matrices with nanogram-level doses of BMP-2, stromal cell-derived factor-1β (SDF-1β), transforming growth factor-β1 (TGF-β1), or co-therapies thereof. We tested the hypothesis that bioprinted SDF-1β co-delivery enhances BMP-2 and TGF-β1-driven osteogenesis both in-vitro and in-vivo using a mouse calvarial critical size defect (CSD) model. Results: Our data showed that BMP-2 bioprinted in low-doses induced significant new bone formation by four weeks post-operation. TGF-β1 was less effective compared to BMP-2, and SDF-1β therapy did not enhance osteogenesis above control levels. However, co-delivery of BMP-2 + SDF-1β was shown to augment BMP-2-induced bone formation compared to BMP-2 alone. In contrast, co-delivery of TGF-β1 + SDF-1β decreased bone healing compared to TGF-β1 alone. This was further confirmed in vitro by osteogenic differentiation studies using MC3T3-E1 pre-osteoblasts. Conclusions: Our data indicates that sustained release delivery of a low-dose growth factor therapy using biopatterning technology can aid in healing CSD injuries. SDF-1β augments the ability for BMP-2 to drive healing, a result confirmed in vivo and in vitro; however, because SDF-1β is detrimental to TGF-β1-driven osteogenesis, its effect on osteogenesis is not universal.
Introduction
Craniofacial wounds resulting from injury trauma or iatrogenic sources (e.g., tumor removal) present a major problem for surgery. Although bone has an innate capacity to heal, large defects in the calvarium are known to present with inadequate bony healing [1] [2] [3] .
Autologous reconstruction has been the standard of care in these cases. However, problems exist with this approach [4] , including the shortage of the amount of available bony tissue that can be harvested from the patient (i.e., ribs or iliac crest) and associated significant morbidities [5] . Allogeneic grafts or synthetic materials (e.g., cadaveric bone and hydroxyapatite) are often used as alternatives despite their limitations, often causing suboptimal outcomes [1] . More recently attention has been paid to growth factor therapies, specifically bone morphogenetic protein-2 (BMP-2), a member of the transforming growth factorbeta (TGF-β) superfamily. BMP-2 (INFUSE, Medtronic, Minneapolis, Minnesota) is FDA-approved for procedures such as sinus augmentation and spinal fusion. BMP-2 has also proved successful in other clinical applications including the treatment of acute, primary calvarial wounds [3, 4, [6] [7] [8] [9] [10] [11] [12] . However, despite its clinical utility, undo complications have been reported [13, 14] . These problems have mostly been associated with the supraphysiological BMP-2 doses utilized clinically to overcome delivery issues [15, 16] . BMP-2 therapies are also extremely expensive, in large part due to the large milligram doses currently used.
There is ongoing research to address the limitations of BMP-2 for healing bony wounds safely and effectively. One approach is the utilization of different growth factors, cytokines, or chemokines, as well as co-therapy strategies including BMP-2 to augment healing. Stromal cell-derived factor-1 (SDF-1/CXCL12) is a member of the CXC chemokine family [17] . SDF-1 and its cognate receptor (CXCR4) are expressed constitutively in various tissues [18] [19] [20] . Among other chemokine pathways, binding of SDF-1 to CXCR4 initiates the recruitment of regenerative cells to injury sites during the acute phase of bone repair [21] [22] [23] . Furthermore, a direct regulatory role for SDF-1 signaling in BMP-2-induced osteogenic differentiation of mesenchymal cells has been reported in vitro [24] [25] [26] and in vivo [27] [28] [29] [30] [31] employing ectopic and orthotopic bone formation models. Transforming growth factor-beta (TGF-β) isoforms have also received some attention. TGF-β1 is a cytokine responsible for the control of cell proliferation of many cell types, including osteoblasts; thus TGF-β1 has osteogenic properties [32, 33] . TGF-β1 is expressed constitutively in healing bone fractures and plays a positive role in bone formation by the stimulation of Runx2, an early marker of osteoblastogenesis [34] [35] [36] [37] [38] [39] . It may however inhibit late stage osteoblast differentiation [40] . Interestingly, TGF-β1 has cell homing properties [32] and has been shown to enhance the ability of SDF-1 in this process [41, 42] .
In this study we investigated the combination of several approaches to augment bone wound healing, including highly-localized co-delivery of multiple growth factors in low-doses. We used established inkjetbased biopatterning technology [43] [44] [45] [46] [47] to controllably load nanogram level doses of BMP-2, SDF-1β, and TGF-β1, or combinations thereof, into acellular DermaMatrix delivery scaffolds, which have native binding affinities for these growth factors. SDF-1β was chosen over the more abundant splice variant SDF-1α due to its greater resistance to proteolytic cleavage conferred by its additional 4 C-terminal amino acids relative to SDF-1α [1, 48, 49] . We tested the hypothesis that SDF-1β co-delivery enhances BMP-2-and TGF-β1-driven osteogenesis both in vitro and in vivo using a mouse calvarial critical size defect (CSD) model.
Materials and methods

Animals
C57BL/6J male mice were purchased from Jackson Laboratories (Bar Harbor, ME, USA). Animals were maintained at the Laboratory Animal Services research facility at Georgia Regents University and used at the age of 8 weeks. All aspects of the research were conducted in accordance with the guidelines set by the local Institutional Animal Care and Use Committee following an approved protocol.
Biopatterning
Bio-inks were printed as defined patterns on the dermal surface of 5-mm diameter discs of acellular DermaMatrix (ADM) (Synthes, West Chester, PA, USA) using our custom inkjet-based biopatterning system, as previously described [43, 50, 47] . Briefly, the deposited concentrations are modulated using an overprinting strategy whereby each location on the pattern is overprinted with dilute bioinks (sodium phosphate buffer, pH 7.4) such that the deposited concentrations increase in proportion to the number of overprinted drops. Deposited inks absorb into the ADM prior to drying, thus patterns are created within the matrix. A semicircular pattern of growth factor(s) was printed on each disc. Each pattern consisted of recombinant human SDF-1β, BMP-2, BMP-2 + SDF-1β, TGF-β1, or TGF-β1 + SDF-1β. The BMP-2 and SDF-1β (Peprotech, Rocky Hill, NJ, USA) patterns were printed with 50 overprints (OPs) of 100 μg/ml bioinks, for a total of 108.5 ng of bound growth factor per pattern. rhTGF-β1 (Peprotech) patterns were printed with 30 OPs, for a cumulative total of 65.1 ng of applied growth factor. Notches were cut in the discs opposite the printed area to maintain orientation upon implantation (Fig. 1a) .
Experiments and study groups
Animals were assigned randomly to one of 6 treatment groups, saline/vehicle control, SDF-1β, BMP-2, BMP-2 + SDF-1β, TGF-β1, and TGF-β1 + SDF-1β. The control group had a sample size of n = 3, all other groups had n = 4.
Mouse calvarial critical size defect model
An established mouse calvarial critical size defect (CSD) model was used to test the ability of the printed growth factors to heal the bony wound [50, [51] [52] [53] . Briefly, the mice were anesthetized and the scalps were shaved and sterilized before surgery. A midline scalp incision was used to expose the periosteum. The periosteum overlying the planned craniectomy defect was excised. Under surgical loupes, a 5-mm craniectomy defect was trephinated in the midline of the parietal bones using a slow-speed hand drill. Meticulous care was taken to ensure that underlying dura was not disturbed. Each craniectomy defect was filled with a printed disc prepared with the assigned treatment as above, with orientation guided by the aforementioned notches allowing for the growth factor printed side to approximate the dura mater (Fig. 1a) . The skin was closed with a 6 × 0 polypropylene suture, and the mice received carprofen (2.5 mg/kg; SC; PRN) for 48 h for postoperative analgesic. The mice were euthanized 4 weeks after surgery, at which point the surgical sites were explanted and subjected to radiographic and micro computed tomography analysis.
Radiographic analysis
Radiographic analysis was performed as described previously [31] . Calvarial specimens were placed in 100-mm cell culture dishes and radiographed using a digital imaging instrument (Faxitron X-Ray, Wheeling, IL, USA) following initial calibration. Percent radiographic bone healing for each defect was estimated using a 5.0-mm region of interest (ROI) and ImageJ software (NIH) (Washington, DC, USA). Using ImageJ, each 5.0-mm ROI was isolated, subjected to system default binary thresholding (white being new bone, black being defect or lack of bone). After thresholding the ROI was halved and each half was measured for amount of new bone. Ratio of new bone was calculated based on the 1/2 area of a 5 mm circle. Percent bone healing measure resulted from the above analysis.
Micro computed tomography
Micro computed tomography (μCT) analysis was performed as described previously [31] . Calvarial specimens were scanned using an ex vivo μCT system (Skyscan 1174; Skyscan, Aartselaar, Belgium). The scanner was equipped with a 50 kV, 800 μA X-ray tube and a 1.3 megapixel CCD coupled to a scintillator. Each sample was placed in a sample holder with the sagittal suture oriented parallel to the image plane and scanned in air using a 0.25-mm aluminum filter, 13-μm isotropic voxels, 1300 ms integration time, 0.5°rotation step, and frame averaging of 4. For 3-D reconstruction (NRecon software, Skyscan), the gray scale was set from 50 to 140. Standard 3-D morphometric parameters [54] (CTAn software, Skyscan) were determined in the ROI (2.5-mm semicircle; 100 cuts). Representative 3-D images were created using CTvox software (Skyscan).
Osteogenic differentiation
Osteogenic differentiation was performed as described previously [26] . MC3T3-E1 Subclone 4 (ATCC® CRL-2593™) murine preosteoblasts (passage 5) were plated at 5.0 × 10 3 cells/cm 2 in 12-well plates using normal proliferation medium comprised of alpha Modified Eagle Medium (αMEM; Cellgro, Mediatech, Manassas, VA, USA) supplemented with 10% heat-inactivated fetal bovine serum (FBS; Atlanta Biologicals, Lawrenceville, GA, USA). Starting the next day, cells were incubated in standard osteogenic induction medium comprised of αMEM supplemented with 5% FBS, 0.25 mM ascorbic acid (Sigma-Aldrich, St. Louis, MO, USA), 0.1 μM dexamethasone (Sigma-Aldrich), and 10 mM β-glycerophosphate (Sigma-Aldrich) for 21 days. The medium was supplemented with 100 ng/ml rhSDF-1β, 100 ng/ml rhBMP-2 (Peprotech), 100 ng/ml rhSDF-1β + 100 ng/ml rhBMP-2, 10 ng/ml rhTGF-β1, 100 ng/ml rhSDF-1β + 10 ng/ml rhTGF-β1 (all from Peprotech), or vehicle control. Of note, rhBMP-2 in the respective groups was only supplied for the first 24 h in culture to avoid over-stimulation of osteogenic differentiation [26] . Induction media were exchanged every 3 days.
Bone mineral nodule formation assay
Alizarin Red S (ARS) staining was performed to identify calcium mineral content as described previously [26] . After 21 days in culture, MC3T3-E1 monolayers were washed with PBS and fixed in 3% paraformaldehyde (Sigma-Aldrich) for 30 min. Cells were stained with 40 mM ARS pH 4.1 (Sigma-Aldrich) for 15 min followed by washing with excess dH 2 O. Stained monolayers were visualized by scanning the plate using a conventional flatbed scanner (Canon, Melville, NY, USA). For quantitative destaining [55] , cells were incubated for 10 min with 10% cetylpyridinium chloride (Sigma-Aldrich). Aliquots were diluted (1:10) with PBS, transferred to a 96-well plate (Nunc, Thermo Fisher Scientific, Waltham, MA, USA), and absorbance was read at 570 nm.
Quantitative reverse transcription-polymerase chain reaction
Cells were treated as above. After 7 days in culture, cells were detached, lysates pelleted and RNA isolated using the Qiagen, RNeasy Plus Kit (Valencia, CA, USA) following standard protocol. An n = 3 of samples was pooled for each treatment. Quantity and quality of RNA were assessed using a Spectrophotometer (Nanodrop 1000, Wilmington, DE, USA). All ratios of absorbance at 260 and 280 nm were greater than 2.0. Quantitative reverse transcription-polymerase chain reaction (qRT-PCR) was run using a one-step kit for cDNA synthesis (Quanta Biosciences, Gaithersburg, MD, USA) and gene expression. A master mix was made from nuclease free water, master mix, RT/Rnase inhibitor and commercially prepared Taqman probe/primer sets (Life Technologies, Grand Island, NY, USA; Table 1 ). Three microliters of RNA was added to the master mix for each gene product for each condition by treatment. Analysis was conducted using the ECO Real Time PCR system (Illumina Inc., San Diego, CA, USA) using the average of duplicates. Expression data was normalized to 18S expression using the comparative C T method. Quantitative data was compared by treatment. mRNA expression for bone formation marker genes Runx2, Alp, Osx, Col1a1, Ocn, Msx2, Dlx5 and Twist1 was analyzed. The primer sequences used are listed in Table 1 .
Statistical analysis
For percent bone healing measured by Faxitron, resulting μCT measures and quantitative Alizarin Red S data, ANOVA with post-hoc Bonferroni multiple comparisons were utilized to determine differences by group. All data are expressed as means ± SD. Differences were considered statistically significant if p b 0.05. For quantitative qRT-PCR following standardized methodology [56, 57] we set expression differences compared to control and between groups as likely biologically significant and thus statistically significant if a 2-fold mean change increase or decrease was observed.
Results
Radiographic and μCT analysis
Representative radiographic images of the calvarial CSDs treated with printed ADM (semicircle per treatment) at 4 weeks are shown in Figs. 1b-g. Quantitative analysis of the newly formed bone within the craniotomy defect revealed limited bone formation in mice treated with SDF-1β, comparable to vehicle controls (Fig. 2) . In contrast, a noticeable increase (~3-fold) in BMP-2-induced bone formation was observed relative to controls, which was potentiated with SDF-1β codelivery (Fig. 2) . Treatment with TGF-β1 improved the healing outcomes compared to vehicle controls but did not reach the levels of BMP-2. Co-delivery of TGF-β1 + SDF-1β attenuated bone formation levels seen with TGF-β1 alone (Fig. 2 ). There was a significant difference in mean healing values by treatment group p = 0.003. Post-hoc analysis revealed BMP-2 + SDF-1β to have significantly greater bone healing than control (p = 0.010), SDF-1β (p = 0.025) and TGF-β1 + SDF-1β (p = 0.011). Ex vivo μCT was then employed to characterize bone formation in more detail. Representative 3-D reconstructions of the calvarial CSDs at 4 weeks post-surgery are depicted in Fig. 3 . Quantitative analyses of standard 3-D bone morphometric parameters concurred with the radiographic estimate and revealed significantly increased percent bone volume (BV/TV) with BMP-2 treatment alone or in combination with SDF-1β relative to vehicle controls (Fig. 4a) . A trend toward potentiating effects of SDF-1β co-delivery on BMP-2 osteoinduction was observed. For BV/TV there was a significant difference by treatment group, p = 0.002. Post-hoc analyses revealed the same significant differences as Faxitron bone healing analysis, i.e., BMP-2 + SDF-1β had significantly greater bone healing than control (p = 0.019), SDF-1β (p = 0.008) and TGF-β1 + SDF-1β (p = 0.015). Trabecular number (Tb.N) appeared to increase with BMP-2 or BMP-2 + SDF-1β compared to controls (Fig. 4b) . There was a significant difference for Tb.N by treatment group, p b 0.001. Post-hoc comparison revealed BMP-2 treatment to have greater trabecular number than control (p = 0.032), SDF-1β (p = 0.014), and TGF-β1 + SDF-1β (p = 0.032); BMP-2 + SDF-1β had greater trabecular number than control (p = 0.005), SDF-1β (p = 0.002), TGF-β1 (p = 0.017) and TGF-β1 + SDF-1β (p = 0.009). Trabecular thickness (Tb.Th) appeared to be markedly reduced in both BMP-2 treated groups relative to vehicle controls (Fig. 4c) . For Tb.Th, these data violated the assumption of homogeneity of variance. A reciprocal square data transformation allowed data to meet this assumption. There were no significant differences for Tb.Th by treatment group, p = 0.086. Trabecular separation (Tb.Sp) appeared to be decreased with BMP-2 or BMP-2 + SDF-1β compared to controls (Fig. 4d ). There was a significant difference for Tb.Sp by treatment, (Figs. 4a and b) . Both Tb.Th and Tb.Sp were decreased with TGF-β1 compared to vehicle controls (Figs. 4c and d) . Co-delivery of SDF-1β distinctly reduced the regenerative potential of TGF-β1, as evidenced by decreased BV/TV and Tb.N, and increased Tb.Th and Tb.Sp (Fig. 4) . No differences in bone morphometric parameters between SDF-1β and vehicle controls were apparent (Fig. 4) .
In vitro osteogenic differentiation
To further investigate the effects of co-delivery of BMP-2 + SDF-1β and TGF-β1 + SDF-1β on osteogenic differentiation in vitro, calvarial MC3T3-E1 pre-osteoblasts were cultured for 21 days in induction medium in the presence of the same treatments used in vivo. Calcium mineral content was assessed using standard Alizarin Red S (ARS) staining (Fig. 5a ). There was a significant difference in quantitative ARS values by treatment group, p b 0.001. In agreement with both radiographic and μCT analysis, osteogenic differentiation of MC3T3-E1 cells was significantly increased with BMP-2 or BMP-2 + SDF-1β treatment compared to all other groups (p b 0.001; Fig. 5b ). SDF-1β co-delivery noticeably potentiated BMP-2-induced mineralization of the preosteoblasts relative to BMP-2 alone but did not reach significant levels. Contrary to the in vivo data, no differences were found between TGF-β1 and TGF-β1 + SDF-1β groups at 21 days of osteogenic differentiation (Fig. 5) . Supplementing SDF-1β to the induction medium had no effect on MC3T3-E1 osteogenic differentiation, as evidenced by similar ARS level relative to vehicle controls (Fig. 5) .
Next, we investigated mRNA expression levels of the key osteogenic markers runt-related transcription factor (Runx) 2, alkaline phosphatase (Alp), osterix (Osx), collagen type 1 alpha 1 (Col1a1), osteocalcin (Ocn), msh homeobox 2 (Msx2), distal less homeobox 5 (Dlx5), and twist 1 (Twist1) during the early stages of MC3T3-E1 osteogenic differentiation (7 days). Relative transcript levels for Runx2 (Fig. 6a) suggest treatments of SDF-1β, BMP-2 + SDF-1β, and TGF-β1 to have elevated expression, and TGF-β1 + SDF-1β to have reduced expression. Also note, the relative increase when SDF-1β is combined with BMP-2 and the decrease when SDF-1β is co-delivered with TGF-β1. Relative transcript levels for Alp (Fig. 6b) indicate BMP-2 therapy alone and BMP-2 + SDF-1β co-therapy to have increased expression, and TGF-β1 and TGF-β1 + SDF-1β to have decreased expression. Again, SDF-1β was found to potentiate the effect of BMP-2, but attenuate the effect of TGF-β1. Relative transcript levels of Osx (Fig. 6c) suggest treatments of BMP-2 and BMP-2 + SDF-1β to have elevated expression with SDF-1β enhancing the effect of BMP-2. Relative transcript levels for Col1a1 (Fig. 6d) indicate treatments of SDF-1β, BMP-2 + SDF-1β, TGF-β1, and TGF-β1 + SDF-1β to have increased expression. Again, note the differential effects of SDF-1β on BMP-2 and TGF-β1 therapies. Relative transcript levels for OCN (Fig. 6e) suggest treatments of BMP-2 and BMP-2 + SDF-1β to have elevated expression, and SDF-1β, TGF-β1 and TGF-β1 + SDF-1β to have reduced expression. SDF-1β cotreatment was found to enhance the effect of BMP-2. Relative transcript levels for Msx2 (Fig. 6f) indicate treatments of BMP-2 and BMP-2 + SDF-1β to have increased expression with SDF-1β potentiating the effect of BMP-2 treatment. Note, however, the relationship for treatments of TGF-β1 and TGF-β1 + SDF-1β combined: TGF-β1 alone decreasing and the combined treatment slightly elevating expression of Msx2. Relative transcript levels for Dlx5 (Fig. 6g) suggest treatments of BMP-2 and BMP-2 + SDF-1β to have elevated expression with SDF-1β synergistically increasing expression when co-delivered with BMP-2. Importantly, the effects of TGF-β1 and TGF-β1 + SDF-1β treatments on Dlx5 appeared to be the opposite compared to Msx2 (Figs. 6f and g ). Relative transcript levels for Twist1 (Fig. 6h) suggest all potentially osteogenic treatment groups BMP-2, BMP-2 + SDF-1β, TGF-β1 and TGF-β1 + SDF-1β to slightly decrease Twist1 expression.
Collectively, SDF-1β co-delivery synergistically augmented BMP-2-induced new bone formation but attenuated the regenerative potential of TGF-β1, indicative of an opposing regulatory role of the CXCR4/SDF-1 signaling axis dependent on the TGF-β superfamily co-stimulator.
Discussion
The aim of the present study was to utilize previously described biopatterning technology [43] [44] [45] [46] [47] to deliver BMP-2, SDF-1β, TGF-β1, or combinations thereof, to investigate their use as potential cotherapies for healing calvarial CSDs. We tested the hypothesis that SDF-1β co-delivery enhances BMP-2-and TGF-β1-driven osteogenesis both in vitro and in vivo using a mouse calvarial CSD model. The in vivo data show that bioprinted low-dose BMP-2 induces significant new bone formation. TGF-β1 was less effective compared to BMP-2, and SDF-1β did not enhance osteogenesis above vehicle control levels. Co-delivery of BMP-2 + SDF-1β was found to augment BMP-2-induced bone formation compared to BMP-2 alone. In contrast, co- delivery of TGF-β1 + SDF-1β decreased bone healing seen with TGF-β1 alone. This observation was further confirmed in vitro by osteogenic differentiation studies using MC3T3-E1 cells.
A major problem in the field of craniofacial surgery is non-healing bony defects. Causes of craniofacial injury include trauma and tumor removal, contributing to prevalent mortality and morbidity [58, 59] . This is further complicated by factors that compromise the recipient wound bed or interfere with optimal healing (e.g., irradiation, infection, surgical damage) [3, 60, 61] . Autologous bone grafts remain the standard of care, although, the process of harvesting is associated with morbidity and a number of complications. Therefore, allogeneic and synthetic bone grafts are often used, despite their disadvantages such as the lack of robust bioactivity, incompatibility, instability, and susceptibility to infection [1] . While BMP-2 therapies address some of these issues, emerging safety concerns have motivated development of alternative strategies for augmentation of clinical bone healing [62] .
Previous studies have suggested that the CXCR4/SDF-1 axis functions in postnatal bone formation by regulating osteoblast development in cooperation with BMP signaling, and that CXCR4 acts as an endogenous signaling component necessary for bone formation [30] . We [26] and others [63] have shown that bone marrow endothelial and stromal cells, and osteoblasts express both major SDF-1 splice variants, and that unexpectedly the beta isoform may be present at a high level in bone tissues [63] . We have also shown that, independent of SDF-1α, SDF-1β enhances BMP-2-stimulated mineralization, mRNA and protein expression of key osteogenic markers, regulates BMP-2 signal transduction via Erk1/2 phosphorylation, and promotes the migratory response of CXCR4-expressing BMSCs in vitro [26] , suggesting both SDF-1β autocrine and paracrine activities. An important characteristic of SDF-1β is its protection from proteolytic cleavage at the C-terminus, distinguishing SDF-1β from SDF-1α. Further, the four additional Cterminal amino acids are thought to mediate SDF-1β cell and extracellular stability, increasing its half-life and potency in vascularized tissues [1, 48, 49] . This suggests that SDF-1, in particular the beta isoform, is of interest in translational approaches to enhance bone formation via the BMP-2 pathway, as recently reported [31] , and may permit low-dose clinical BMP-2 therapies with reduced negative side effects [8, 64] .
Our in vivo data, obtained using the established CSD [50, [51] [52] [53] , suggest that biopatterned BMP-2 at a low-dose induces significant new bone formation, while TGF-β1 only moderately improved the outcome. SDF-1β does not induce osteogenesis, as evidenced by comparable levels of bone formation to vehicle controls. Importantly, BMP-2 + SDF-1β co-therapy was found to augment BMP-2-induced bone formation, thereby confirming previous findings from our group across species (rat vs. mouse) and delivery technologies (absorbable collagen sponge (ACS) vs. ADM; soak-loaded vs. bioprinted) [31] . To that end, it is critical to point out that the BMP-2 dose printed on ADM (11.1 ng/mm 2 ) used in this study was comparable to the suboptimal BMP-2 dose soak-loaded on ACS (9.9 ng/mm 2 ) previously described [31] . Despite the similar absolute BMP-2 dose per matrix/defect, the observed outcomes were distinctly different. While we found robust osteoinduction using the biopatterned low-dose BMP-2 on ADM, no significant bone formation was apparent using the suboptimal soak-loaded BMP-2 on ACS in the rat model after the same 4-week healing interval [31] . These observations can be extended with respect to the SDF-1β doses used in both studies. SDF-1β was printed here on ADM at the same 11.1 ng/mm 2 , which significantly enhanced the osteoinductive properties of low-dose BMP-2. In contrast, the therapeutic dose range of SDF-1β co-delivered with suboptimal BMP-2 dose far exceeded the bioprinted SDF-1β dose (298.2-1192.8 ng/mm 2 ; 27-107-fold increased) [31] . This suggests that the biopatterning technology allows for the use of very low therapeutic doses of BMP-2 and SDF-1β in the nanogram range, validating previous reports [31, 50, 53] . With regard to the release kinetics of the biopatterned cytokines, our group has previously reported that after 24 h of incubation in standard cell culture medium at 37°C,~80% of the biopatterned BMP-2 remained bound to the ADM with subsequent slow release over 14 days such that~70% of bound BMP-2 remained [53] . Therefore, the retention of biopatterned BMP-2 on ADM appears to be significantly longer than what is generally reported for soak-loaded BMP-2 on ACS. A recent study showed that only~20% of the soak-loaded BMP-2 remains bound to the ACS after 6 days in vitro [65] . Comparable short retention times have been described in vivo using both ectopic (6 days;~10%) [66] and orthotopic (7 days;~30%) [67] bone formation models. Collectively, the inkjetbased biopatterning technology combined with the ADM delivery system may protect the printed cytokines until solubilized, and allow a prolonged retention and an extended bioavailability compared to other technologies. A key component of this study was the inclusion of another TGF-β superfamily member, TGF-β1, used as stand-alone as well as combination therapy. TGF-β1 regulates cell proliferation and migration of different cell types, including osteoblasts. Therefore, TGF-β1 has osteogenic properties [32, 33] . TGF-β1 is expressed constitutively in healing bone fractures and is involved in bone formation by stimulating Runx2 [34] [35] [36] [37] [38] [39] . In agreement with this, we observed enhanced bone formation using biopatterned TGF-β1 compared to vehicle controls. Unexpectedly, co-delivery of TGF-β1 + SDF-1β attenuated the therapeutic effects of TGF-β1 in vivo. We further confirmed these relationships between the cytokines in vitro by standard Alizarin Red S (ARS) staining of mineralization and transcript analyses of key osteogenic markers in murine calvarial MC3T3-E1 pre-osteoblasts. ARS staining for calcified nodules at 21 days was generally in agreement with the in vivo findings, although the reduction in mineralization with co-delivery of TGF-β1 + SDF-1β compared to TGF-β1 alone was less pronounced.
Consistent with the expression of BMP and TGF-β receptors in mesenchymal cells and osteoblasts, both BMP-2 and TGF-β1 regulate osteogenic differentiation albeit using different signal transduction pathways. Several transcription factors are sequentially expressed during BMP-induced osteoblast differentiation and are required for cell maturation. Among these, Runx2 and Osx are considered master switches in osteoblastogenesis, which can directly be upregulated by BMPs and subsequently activate downstream genes necessary for the osteoblast phenotype such as Col1a1 and Ocn [68] . The expression of Msx2 is rapidly induced in response to BMP-2, which plays an important role in promoting osteoblast commitment [69] , as evidenced by Msx2 directly targeting Ocn [70] . Furthermore, Msx2 has been suggested to inhibit Dlx5 regulation of BMP-2-mediated osteogenesis and inhibit osteoblast differentiation [39, 68] . Dlx5 is specifically expressed in differentiating osteoblasts and binds the Runx2 promoter to confer BMP-2 osteoinduction [39] . Our data suggest that SDF-1β co-delivery enhances BMP-2-induced expression of Runx2, Alp, Osx, Col1a1, Ocn, Msx2, and Dlx5 in pre-osteoblasts relative to BMP-2 alone, confirming previous findings from our group using mesenchymal stem cells [26] . We also observed down-regulation of Twist1 for all cell treatments with the exception of SDF-1β alone. This is a confirmatory finding for the maturation of the pre-osteoblasts toward their final phenotype as Twist is a marker of stemness of cells [71] . In contrast, SDF-1β appears to act to limit further differentiation decreasing Runx2 expression when co-delivered with TGF-β1 compared to TGF-β1 administration alone. This appears to result in less Alp, Col1a1, and Dlx5 expression. Although possibly not biologically significant (within ± 2-fold change), we found opposing patterns of Msx2 and Dlx5 expression suggesting a potential role for SDF-1β in contextually eliciting differential effects on the expression of these important transcription factors. Taken together, we observe what might represent a rescue effect with reference to late stage differentiation, specifically Ocn expression. TGF-β1 has previously been shown to inhibit late stage differentiation, an effect we confirmed here in vitro [39, 68] . It may be that setting up the healing axis and inhibition of early Runx2 expression with TGF-β1 + SDF-1β co-treatment may underlie our observed outcome of reduced healing. However, we can only speculate on the detailed molecular pathways involved, this points to future areas of investigation.
Collectively, our data suggest that SDF-1β co-therapy synergistically augments BMP-2-induced new bone formation but attenuates the regenerative potential of TGF-β1, indicative of an opposing regulatory role of the CXCR4/SDF-1 signaling axis dependent on the TGF-β superfamily co-stimulator. Given the numerous adverse effects reported with current commercial high-dose BMP-2 products, including significant inflammatory and immunogenic responses [8, 64] , the opportunities to significantly reduce the locally applied BMP-2 dose for bone regeneration using biopatterning technology present an intriguing avenue for translational development.
Conclusion
SDF-1β enhances BMP-2-driven osteogenesis and bone healing in a mouse critical size calvarial defect model. It does not, however, improve healing utilizing a TGF-β1 based therapy. SDF-1β augments the positive effects that BMP-2 has on osteogenic gene expression but reduces those same positive effects for TGF-β1. This relationship between SDF-1β and opposing effects on different members of the TGF-β superfamily necessitates further investigation to determine what downstream targets are affected by SDF-1β and how this translates to differences in bony healing and if it contributes to clinical impaired healing, i.e. in diabetes or aging.
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